(Q64858738)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10430055%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

title

Effects of amantadine treatment on in vitro production of interleukin-2 in de-novo patients with idiopathic Parkinson's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10430055%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference

K P Wandinger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10430055%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

J M Hagenah

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10430055%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

H Klüter

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10430055%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

M Rothermundt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10430055%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

M Peters

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10430055%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

P Vieregge

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10430055%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

publication date

1 August 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10430055%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuroimmunology

10 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10430055%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

volume

98

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10430055%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10430055%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

page(s)

214-220

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10430055%20AND%20SRC:MED&resulttype=core&format=json

Amantadine in advanced Parkinson's disease: good use of an old drug.

10 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Interleukin-2 modulates evoked release of [3H]dopamine in rat cultured mesencephalic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

A correlation study between serum adenosine deaminase activities and peripheral lymphocyte subsets in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

In vitro secretion of interleukin-1 beta and interferon-gamma by peripheral blood lymphomononuclear cells in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Parkinson's disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Parkinsonism: onset, progression, and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Association of in vitro immune functions with the severity of the disease in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Acquired defect in interleukin-2 production in patients with type I diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

A whole-blood technique for testing production of human interferon by leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Defective production of interleukin-2 in patients with idiopathic Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Adoptive immunotherapy with IL-2 results in the loss of delayed-type hypersensitivity responses and the development of immediate hypersensitivity to recall antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

A role for interleukin-2 in the regulation of striatal dopaminergic function

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

(R)salsolinol N-methyltransferase activity increases in parkinsonian lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Interleukin-2 production and interleukin-2 receptor expression in children with newly diagnosed diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Kinetics of cytokine secretion by mononuclear cells of the blood from rheumatoid arthritis patients are different from those of healthy controls

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Interleukin-2: inception, impact, and implications

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

The IL-2/IL-2 receptor system: a current overview

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

Involvement of cytokines in normal CNS development and neurological diseases: recent progress and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900093-4

7 January 2021

10.1016/S0165-5728(99)00093-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10430055%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference